4/26/2010

Advanced Cell Technology reported that its Stargardt's macular dystrophy treatment, which uses retinal pigment epithelium cells, did not cause any side effects in animal subjects. The biotech firm plans to launch human trials of the stem cell therapy in Oregon, New Jersey and Massachusetts.

Related Summaries